Vardenafil improves erectile function in men with erectile dysfunction irrespective of disease severity and disease classification

Craig Donatucci, Ian Eardley, Jacques Buvat, Marc Gittelman, Phillip Kell, Thom Segerson, Martin Homering, Francesco Montorsi, Roger De Bruyne, Georges Declercq, Dirk Vanderscheuren, Francis Duyck, Benny Verheyden, Eric Wespes, Thomas Gerstenberg, Overlæge Peter Lyngdorf, Francois Giuliano, Beatrice Cuzin, Albert Leriche, Pierre BondilPierre Costa, Thierry Lebret, Emmanuel Blanc, Olivier Lan, Robert Porto, Kanaiyalal Desai, Wilbert Dinsmore, Roger Kirby, M. Speakman, David Ralph, Geoffrey Hackett, Vincenzo Mirone, Francesco Paolo Selvaggi, Giorgio Carmignani, Francesco Francesca, Fabrizio Menchini Fabris, Enrico Pisani, Guglielmo Breda, Emanuele Belgrano, Gaetano Frajese, Arcangelo Pagliarulo, Vincenzo Gentile, Vincenzo Bonifacio, R. F. Kropman, E. J.H. Meuleman, H. Asscheman, Kazimierz Krajka, Andrzej Borkowski, Christer Dahlstrand, Peter Ekman, Björn Lundquist, Randall P. Abele, Gerald L. Andriole, Stephen M. Auerbach, Jack Barkin, Winston Barzell, Donald Bergner, Richard Casey, Stacy Childs, Selwyn Cohen, David O. Cook, Jeoffrey Deeths, Mostafa Elhilali, Pamela I. Ellsworth, Howard B. Epstein, Robert A. Feldman, Louis Fields, Roger Fincher, William III Fitch, Jenelle E. Foote, Jeffrey Frankel, Harold A. Fuselier, Larry I. Gilderman, Evan Goldfischer, James E. Gottesman, Fred Govier, Michael Greenspan, Wayne J. Hellstrom, Charles B. Herring, Gary S. Karlin, Joel M. Kaufman, Robert J. Krane, John N. Krieger, Alan Lau, William A. Leitner, Joel Lilly, Jack Lubensky, Nizamuddin Maruf, Keith Matthews, Kevin T. McVary, Andrew McCullough, Arnold Melman, William B. Monnig, Craig Niederberger, Harin Padma-Nathan, Allan B. Patrick, Jon Lee Peterson, Peter J. Pommerville, V. Gary Price

Research output: Contribution to journalArticle

32 Scopus citations

Abstract

Background. Vardenafil (Levitra®) is a potent and selective phosphodiesterase 5 (PDE5) inhibitor used in the management of erectile dysfunction (ED). This retrospective subgroup analysis assessed the effectiveness of vardenafil treatment in men with ED of different baseline severity and disease classification. Methods. Data from two pi votal, randomized, double-blind, placebo-controlled clinical trials enrolling men from the general ED population who received placebo or vardenafil 5 mg, 10 mg, or 20 mg during a 12-week treatment period were retrospectively analysed, stratifying by psychogenic, organic, and mixed ED disease classification as determined by the investigator. Efficacy endpoints included the International Index of Erectile Function (IIEF)-Erectile Function (EF) domain score, per-patient diary response rates to questions on penile insertion [Sexual Encounter Profile (SEP-2)] and maintenance of erection (SEP-3) and rates of positive response to the Global Assessment Question (GAQ). Results. Data from 1,385 men who received at least one dose of study medication and had pre-and post-baseline measures of efficacy available (intent-to-treat population) are presented. At baseline 37-41% of patients had severe ED, 30-34% moderate, 22% mild-to-moderate and 6-8% mild ED. At baseline, 46-51% of patients were considered to have an organic cause for ED, 13-16% psychogenic ED, and 36-38% mixed classification of ED. For all classifications and for mild-to-moderate to severe ED, men treated with 10 or 20 mg of vardenafil showed statistically and clinically significant improvements (P < 0.001) in IIEF-EF scores, diary response rates to the SEP-2 and SEP-3 questions, and GAQ as compared with those given placebo. The greatest improvements relative to placebo were noted in patients with more severe ED. The most common treatment-emergent adverse events were headache, flushing, rhinitis, dyspepsia, and were dose-related, mostly mild to moderate in intensity and consistent with the class. Conclusions. Vardenafil improv es EF in men with ED irrespective of investigator-determined classification and baseline ED severity.

Original languageEnglish (US)
Pages (from-to)301-309
Number of pages9
JournalJournal of Sexual Medicine
Volume1
Issue number3
DOIs
StatePublished - 2004

Keywords

  • Disease classification
  • Erectile dysfunction
  • Vardenafil

ASJC Scopus subject areas

  • Reproductive Medicine
  • Obstetrics and Gynecology
  • Urology

Fingerprint Dive into the research topics of 'Vardenafil improves erectile function in men with erectile dysfunction irrespective of disease severity and disease classification'. Together they form a unique fingerprint.

  • Cite this

    Donatucci, C., Eardley, I., Buvat, J., Gittelman, M., Kell, P., Segerson, T., Homering, M., Montorsi, F., De Bruyne, R., Declercq, G., Vanderscheuren, D., Duyck, F., Verheyden, B., Wespes, E., Gerstenberg, T., Lyngdorf, O. P., Giuliano, F., Cuzin, B., Leriche, A., ... Price, V. G. (2004). Vardenafil improves erectile function in men with erectile dysfunction irrespective of disease severity and disease classification. Journal of Sexual Medicine, 1(3), 301-309. https://doi.org/10.1111/j.1743-6109.04043.x